ADC Therapeutics (ADCT) Change in Receivables (2020 - 2026)

ADC Therapeutics (ADCT) has reported Change in Receivables for 7 consecutive years, with $1.9 million the latest figure, recorded in Q1 2026.

• Quarterly Change in Receivables fell 83.15% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$728000.0 (down 108.4% YoY) and the FY2025 annual result came in at $8.8 million, up 284.22% from the prior year.
• Change in Receivables declined to $1.9 million in Q1 2026 per ADCT's latest filing, from $6.2 million in the prior quarter.
• Over the last five years, Change in Receivables for ADCT reached as high as $35.8 million in Q4 2022 and fell as low as -$48.9 million in Q1 2023.
• A 5-year average of $53529.4 and a median of -$188000.0 in 2023 frame the typical range for Change in Receivables.
• The largest YoY upside for Change in Receivables was 673.68% in 2025 against a maximum downside of 1648.28% in 2025.
• Year by year, Change in Receivables stood at $35.8 million in 2022, then slumped by 88.84% to $4.0 million in 2023, then tumbled by 192.87% to -$3.7 million in 2024, then jumped by 266.63% to $6.2 million in 2025, then slumped by 68.84% to $1.9 million in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered $1.9 million, $6.2 million, and -$3.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.